CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Follow-Up Questions
Who is the CEO of CalciMedica Inc?
Dr. A. Rachel Leheny is the Chief Executive Officer of CalciMedica Inc, joining the firm since 2023.
What is the price performance of CALC stock?
The current price of CALC is $3.21, it has decreased 0% in the last trading day.
What are the primary business themes or industries for CalciMedica Inc?
CalciMedica Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is CalciMedica Inc market cap?
CalciMedica Inc's current market cap is $44.8M
Is CalciMedica Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for CalciMedica Inc, including 3 strong buy, 6 buy, 1 hold, 0 sell, and 3 strong sell
